Barbati A, Cosmi E V, Sidoni A, Collini P, Porpora M G, Ferri I, Lüthy M, Lauro V, Bucciarelli E
Institute of Gynecology and Obstetrics, University of Perugia, Italy.
Anticancer Res. 1997 Jan-Feb;17(1A):401-5.
p53 and c-erbB-2 protein expression was immunohistochemically examined in a consecutive series of 49 primary breast cancer patients with a 10-year follow-up. The study was performed on paraffin sections using the monoclonal antibodies DO7 and CBE1; the former recognizes both the wild-type and the mutant p53 forms, the latter recognizes the external domain of the transmembrane c-erbB-2 protein. Positive staining was expressed in 12.2% and 16.3% of cases for p53 and c-erbB-2 proteins, respectively. The results were related to clinicopathological parameters by the chi 2 test. A significant correlation was found between positive c-erbB-2 immunostaining and poor survival (P = 0.04) and between p53 and c-erbB-2 overexpression (P = 0.003); this co-overexpression correlated well with a poor clinical outcome (P = 0.040). From our results, we may speculate that simultaneous expression of p53 and c-erbB-2 oncoproteins could be a critical event in breast tumor progression, and therefore, of prognostic value to identify patients at high risk.
对连续的49例原发性乳腺癌患者进行了10年随访，采用免疫组织化学方法检测p53和c-erbB-2蛋白表达。研究在石蜡切片上使用单克隆抗体DO7和CBE1进行；前者识别野生型和突变型p53形式，后者识别跨膜c-erbB-2蛋白的胞外结构域。p53和c-erbB-2蛋白阳性染色分别在12.2%和16.3%的病例中出现。通过卡方检验将结果与临床病理参数相关联。发现c-erbB-2免疫染色阳性与生存期差之间存在显著相关性（P = 0.04），p53和c-erbB-2过表达之间也存在显著相关性（P = 0.003）；这种共同过表达与不良临床结局密切相关（P = 0.040）。根据我们的结果，我们可以推测p53和c-erbB-2癌蛋白的同时表达可能是乳腺肿瘤进展中的关键事件，因此，对于识别高危患者具有预后价值。
